Motley Fool Money Tesla Shareholders Are Nervous (They Should Be)
Dec 14, 2022
Joining the discussion is Bill Mann, a Senior Analyst at Motley Fool, who brings expert insight into today’s investment landscape. He highlights Tesla shareholders' growing anxieties as Elon Musk's attention shifts toward Twitter, indirectly affecting Tesla’s stock, which has plummeted since April. Mann also contrasts this with Delta Airlines' optimistic financial outlook and celebrates Moderna's promising advancements in skin cancer treatment, showing that while some stocks suffer, others are gaining ground impressively.
AI Snips
Chapters
Transcript
Episode notes
Delta's Optimistic 2023 Forecast
- Delta Airlines predicts a strong 2023, expecting doubled earnings and a 20% revenue increase.
- This optimism contrasts with the struggles of other airlines like United, highlighting Delta's unique position.
Promising Results from Moderna's Skin Cancer Treatment Trial
- Moderna's skin cancer treatment trial, combining their vaccine with Merck's drug Keytruda, showed promising results.
- The trial indicated a 44% risk reduction in cancer recurrence or death, offering hope for personalized cancer treatment.
Biotech Investment Strategy
- Investing in bleeding-edge biotech companies can be risky due to the high failure rate.
- Consider investing in established companies like Merck, who also benefit from successful drug developments.